Amgen’s FTC Settlement To Allow $27.8bn Horizon Deal Closure Sets New M&A Precedent
Transaction Expected To Conclude Early In Q4
Amgen agreed not to include Horizon’s Tepezza and Krystexxa in rebate bundling deals with payers, among other terms, so the FTC would clear the companies’ merger, giving pharma firms a new consideration in future dealmaking.
